Lauren C. Nigro, MD, Michael J. Feldman, MD, Robin L. Foster, MD, and Andrea L. Pozez, MD
Suspected child abuse cases can be identified and repeat hospitalizations of such cases prevented using multidisciplinary teams to evaluate pediatric burns.
AMA J Ethics. 2018; 20(6):552-559. doi:
10.1001/journalofethics.2018.20.6.org1-1806.
Despite a tendency to react otherwise, there is no obvious reason to believe that economically disadvantaged people ought not to be exposed to the same levels of research risk as the rest of the population.
Public and private choices about allocation of funds for research raise a social-justice question: are these funding sources making fair decisions about where to invest their resources? The NIH has the clearest obligation to do so because it is taxpayer-supported.
The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018; 20(9):E826-833. doi:
10.1001/amajethics.2018.826.
More frequent use of robotic-assisted surgeries means we need to ask more questions about care quality and equity, informed consent, and conflicts of interest.
AMA J Ethics. 2023; 25(8):E605-608. doi:
10.1001/amajethics.2023.605.